ADDRESSING THE CRITICAL NEED FOR NOVEL ANTIMICROBIAL THERAPEUTICS

Bisphosphocins have the potential to save billions of dollars in hospital stays and lengthy treatments versus conventional standard of care antibiotics.

KILLING MULTIDRUG RESISTANT BACTERIA AND FUNGI IN MINUTES

KILLING MULTIDRUG RESISTANT BACTERIA AND FUNGI IN MINUTES

Bisphosphocins directly disrupt microbial cell membranes, leading to fast and safe eradication of infections.

DEVELOPING SOLUTIONS FOR THE ANTIBIOTIC RESISTANCE CRISIS

DEVELOPING SOLUTIONS FOR THE ANTIBIOTIC RESISTANCE CRISIS

Our novel approach is to treat locally, administering highly-effective bisphosphocins directly at the site of infection.

/ 3 / 3

WHO WE ARE

Our expert leadership team is dedicated to developing world-class antimicrobials

With over 100 years of combined pharmaceutical industry experience, our leadership team has the expertise to efficiently bring bisphosphocins to market.

WHAT WE DO

We develop novel antimicrobial therapies for those who need them the most

A rapid and safe topical bactericide and fungicide has the potential to save millions of lives.

HOW WE DO IT

Bacterial and fungal infections are swiftly eliminated directly at the site of infection

Bisphosphocins rapidly kill bacteria and fungi by depolarizing microbial cell membranes, leading to cell death within minutes.

Addressable Patient Populations (US)

1800000

Chronic Diabetic Foot Ulcers (cDFU)

65000

Oral Mucositis

450000

Catheter-related UTI

30000

Cystic Fibrosis (CF)

Stock News Now

Published on Feb 23, 2018
SNNLive spoke with Steve Parkinson, President and CEO of Lakewood-Amedex Inc., a private company, at the BIO CEO & Investor Conference 2018 in New York City, NY.

IN THE NEWS

  • Steve Parkinson, President and CEO of Lakewood-Amedex (a privately-held, clinical stage pharmaceutical company), discusses their development of a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called bisphosphocins™.

    Health Professional Radio - https://healthprofessionalradio.com.au/lakewood-amedex-clinical-stage-pharmaceutical-company/

  • Lakewood-Amedex, Inc. Advances Bisphosphocin Nu-8 to IND-Enabling Studies to Treat Complicated Urinary Tract Infection

    PR NEWSWIRE

  • Lakewood-Amedex, Inc. to Present at 2018 BIO CEO & Investor Conference

    PR NEWSWIRE